Skip to main content
Equibles
SGP logo

SGP · SpyGlass Pharma, Inc.

Track SGP — free

Use SGP with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SGP.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$24.92 +0.30 (+1.22%)
Russell 2000 member Rebalance outlook locked
Market Cap
$823.49M
Shares
33.45M
Volume · Oct 9 68.26K Avg daily vol (3M) 110.41K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$24.62 Open$23.56 Day$23.29–24.84 Available close range$17.56–29.68 Avg vol 30d129K Short int1.3M · 3.7% float · 7.1d Short vol68% Last earningsMay 26, 2026 DataFeb 2026–Oct 2026 Filing10-Q · Aug 6

The closing range uses available history since Feb 6, 2026; less than a full year is stored.

Up next

Latest filing: 10-Q
filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$56.05M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-6.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$223.14M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1,368.2%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
3.7%
Latest settlement · 7.1 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 15.4 · calm Equity put/call 0.62
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 50-day avg −7%
below
RSI (14) 41
neutral
MACD trend Negative
52-week position 58%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −10%
trailing
6-month return −1%
trailing
Relative strength −10%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
2 of 52 funds reported for Sep 30 · net +34 sh shares · +2 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
3.75% of float · ▲ +2.0% MoM · 7.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
52 holders — 13F breadth
Squeeze score 59
elevated · 0–100
Fundamentals
Poor
EPS growth −10%
Y/Y
Free cash flow $-33.5M
Quant / Vol
risk profile
Very High
Volatility 62%
annualized · 1-yr
Max drawdown −41%
past year
ATR 6.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
−7% Bearish
RSI (14)
41 Neutral
MACD trend
Negative Bearish
52-week position
58% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
2 of 52 funds reported for Sep 30 · net +34 sh shares · +2 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
3.75% of float · ▲ +2.0% MoM · 7.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
52 holders — 13F breadth
Price context
position in its available closing range
Range low $18 Now $25 · 58% Range high $30
vs 50-day avg -7%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SGP
SpyGlass Pharma, Inc.
this stock
$823.49M — — — 3.7%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $127.55B +11.0% +46.2% 29.3 1.8%
MRNA
Moderna, Inc.
 $78.65B +568.0% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $76.14B -4.2% +20.8% 18.3 2.1%
CSLLY
Csl Ltd
 $61.58B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
54
% held
78.1%
Reported
2 of 52
Top holder
RA CAPITAL MANAGEMENT, L.…
Held Float
View
Held by Funds
Fund positions
81
View
Short & Settlement
Short Interest Rising
Shares short
1.3M
Days to cover
7.1d
Change
+24.0K sh
View
Short Volume
Short vol %
68%
As of
Oct 9, 2026
Short Total
View
Fails to Deliver
FTD shares
138
Value
$3.8K
As of
Sep 14, 2026
View
Off-Exchange
Off-exchange %
40.5%
Week of
Aug 31, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-39.9M
EPS diluted
$-17.98
View
Filings
SEC Filings
Latest
8-K
Filed
Oct 1, 2026
This year
13
View
Exempt Offerings
Offering
$75.0M
Filed
Jun 5, 2025
View
Earnings & Events
Webcasts
Last webcast
Sep 10, 2026
View

Performance

5D 20D 120D MTD YTD
SGP -7.1% -9.9% -1.3% -5.3% —
SPY +1.3% +2.1% +9.0% +1.5% +13.5%
vs SPY -8.4% -12.0% -10.3% -6.8% —
Key facts CIK 1778922 CUSIP 85220G109 13F (30d) 4 filings 4 filers Visit website Investor relations